Cantor Fitzgerald raises Supernus Pharmaceuticals stock price target on ONAPGO outlook
PositiveFinancial Markets

Cantor Fitzgerald has raised its stock price target for Supernus Pharmaceuticals, driven by a positive outlook on the company's ONAPGO product. This adjustment reflects confidence in Supernus's growth potential and the anticipated success of ONAPGO in the market, which could lead to increased investor interest and potentially higher stock performance. Such developments are crucial as they indicate the company's strategic direction and its ability to innovate in the pharmaceutical sector.
— Curated by the World Pulse Now AI Editorial System